Transcatheter vs. Surgical Aortic Valve Replacement in the UK: No Major Surprises at 1 Year

A large pragmatic trial demonstrates similar 1-year survival and predictable differences in other outcomes.

Transcatheter aortic valve replacement (TAVR) is approved for treatment of severe, symptomatic aortic stenosis across the spectrum of surgical risk and is currently the dominant form of aortic valve replacement in the U.S. and many European countries. However, the evidence supporting this practice is based entirely on industry-sponsored regulatory trials that have strict inclusion criteria and were conducted almost exclusively at expert centers in the U.S. Whether these findings translate to other healthcare systems and can be generalized across a broad range of hospitals is unknown.

To address these areas of uncertainty, U.K. investigators designed a pragmatic trial of TAVR versus surgical aortic valve replacement (SAVR) among patients aged…

Reviewing Author

David J. Cohen, MD, MSc

Disclosures

Consultant/Advisory BoardMedtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; St. Francis Hospital

Speaker’s BureauBoston Scientific; ZOLL Medical

Grant/Research SupportEdwards Lifesciences; Abbott Vascular; Boston Scientific; Corvia Medical; National Heart, Lung, and Blood Institute; Phillips, Inc.; St. Paul’s Hospital; V-Wave, Inc; ZOLL Medical; CathWorks, ANCORA

Editorial BoardsJACC; American Heart Journal; EuroIntervention; JSCAI; Structural Heart Journal

Leadership Positions in Professional SocietiesSociety of Thoracic Surgeons/American College of Cardiology TVT Registry (Co-Chair, Risk Model Development Committee); Cardiovascular Research Foundation (Co-Director, TCT Annual Meeting; Co-Director, New York Valves Annual Meeting)